Skip to main content
OpenTrials
Completed

NCT Number: NCT02625103

The Significance of Deviation in Time From the 12-hour Standard Serum-clozapine Monitoring.

The role of Therapeutic Drug Monitoring (TDM) in clozapine dose adjustment have been debated. Blood samples for s-clozapine monitoring should be drawn 12 hours post dose.

The scope of this trial is to describe changes of s-clozapine and s-N-desmethyl-clozapine within the range of 10-14 hours after the last administration of clozapine .

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–64 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Psychiatric Centre Rigshospitalet

Copenhagen, København Ø, 2100, Denmark

About this study

Several factors can influence s-clozapine and thereby the occurence of dose-related adverse reactions and level of treatment response. The role of Therapeutic Drug Monitoring (TDM) in clozapine dose adjustment have been debated. Blood samples for s-clozapine monitoring are recommended to be drawn 12 hours post dose. Uncertainty regarding the timing of blood sampling and the individual pharmakokinetics for clozapine +/- 2 hours from the 12-hour timepoint, leads to uncertainty regarding the comparability of serum concentrations and the information hold within them.

The scope of this trial is to describe changes of s-clozapine and s-N-desmethyl-clozapine within the range of 10-14 hours after the last administration of clozapine .

In addition we want to investigate if any of the following covariates might affect the change of s-clozapine and s-N-desmethyl-clozapine: Sex, age, BMI, co-medications, signs of infection, caffeine intake and smoking.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 < 65
  • Diagnosed with schizophrenia according to the criteria of ICD10 (International Classification of Diseases, World Health Organization) or the DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, the American Psychiatric Association)
  • Unchanged dose of clozapine for the last 30 days
  • Usual time of clozapine evening-dose administration between 9 and 12 pm.

Exclusion criteria

  • Significant drug or alcohol abuse that affects participation in this trial
  • Non- or partial compliance of clozapine the day before the trial (assessed by interview)
  • Unresponsive by telephone the evening before the trial
  • Consumption of clozapine in the morning on the day of the trial
  • Significant change in smoking habits within the last 30 days (assessed by interview)
  • Significant change of caffeine intake within the last 7 days (assessed by interview)
  • Modified use of other antipsychotics within the last 30 days
  • Within the last 30 days (7 days for hormone based contraceptives) changes in the use of other medications that can affect s- clozapine during the trial : ( fluvoxamine, ciprofloxacin, hormone based contraceptives, carbamazepine , phenytoin , rifampicin, omeprazole )
  • Females who are pregnant or breast-feeding

Treatment and study plan

blood sampling

Procedure

blood samples for s-clozapine and s-desmethyl-clozapine analysis are collected at 10, 11, 12, 13 and 14 hours post evening-clozapine-administration

Clozapine

Drug

Registration of the exact time of drug administration. Also postponement of any morning clozapine administration until ended blood sampling.

Other names: Leponex

Primary outcomes

  1. Percentage change in serum-clozapine

    Time frame: 10 - 14 hours post drug administration

Secondary outcomes

  1. Percentage change in serum-clozapine (multiple shorter ranges)

    Time frame: < 10 -14 hours post dose

Sponsors and collaborators

Lead sponsor

Anders Fink-Jensen, MD, DMSci

Other

Collaborators

  • Rigshospitalet, Denmark
  • University of Copenhagen

Registry information

Official study title

The Significance of Deviation in Time From the 12-hour Standard Serum-clozapine Monitoring

Important dates

Study start
2015
Primary completion
2015
Study completion
2016
First posted
Dec 9, 2015
Registry last updated
Feb 25, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.